TLDR Gates Foundation Trust dumped 17 million Microsoft shares in Q3, reducing holdings from $13.9B to $4.76B Microsoft fell to the trust’s fourth-largest position after years as the top holding The trust has sold Microsoft stock every quarter since late 2023 Sales appear linked to the foundation’s goal of increasing annual grants to $9 billion [...] The post Microsoft (MSFT) Stock: Gates Foundation Offloads $9 Billion in Shares During Q3 appeared first on Blockonomi.TLDR Gates Foundation Trust dumped 17 million Microsoft shares in Q3, reducing holdings from $13.9B to $4.76B Microsoft fell to the trust’s fourth-largest position after years as the top holding The trust has sold Microsoft stock every quarter since late 2023 Sales appear linked to the foundation’s goal of increasing annual grants to $9 billion [...] The post Microsoft (MSFT) Stock: Gates Foundation Offloads $9 Billion in Shares During Q3 appeared first on Blockonomi.

Microsoft (MSFT) Stock: Gates Foundation Offloads $9 Billion in Shares During Q3

TLDR

  • Gates Foundation Trust dumped 17 million Microsoft shares in Q3, reducing holdings from $13.9B to $4.76B
  • Microsoft fell to the trust’s fourth-largest position after years as the top holding
  • The trust has sold Microsoft stock every quarter since late 2023
  • Sales appear linked to the foundation’s goal of increasing annual grants to $9 billion by 2026
  • External managers at Cascade Investments handle trading decisions, not Bill Gates directly

The Gates Foundation Trust made waves with a massive Microsoft stock sale in the third quarter. The foundation unloaded roughly 17 million shares, cutting its stake by 65%.


MSFT Stock Card
Microsoft Corporation, MSFT

The position shrank from $13.9 billion to $4.76 billion. Microsoft tumbled from the trust’s largest holding to fourth place.

Bill Gates co-founded Microsoft but left day-to-day operations in 2008. His foundation trust manages nearly $50 billion in total assets.

Berkshire Hathaway now leads the trust’s portfolio at $10.9 billion. Waste Management and Canadian National Railway also rank above Microsoft.

The Q3 sale generated roughly $8.8 billion in proceeds. The trust also reduced other positions and completely exited Crown Castle and United Parcel Service.

A Pattern of Consistent Selling

This wasn’t a one-time move. The Gates Foundation Trust has sold Microsoft shares every quarter since the end of 2023.

Cascade Investments runs the trust’s portfolio management. Bill Gates doesn’t make individual trading decisions.

The trust did break its selling pattern once. It purchased nearly 40 million Microsoft shares in 2022.

Before that purchase, the trust regularly sold Microsoft stock quarterly for years. The current selling wave follows that historical trend.

The Charitable Spending Connection

The foundation plans to boost annual grantmaking to $9 billion by 2026. It aims to spend down its entire endowment by 2045.

These commitments require steady cash flow. Reducing concentration in one stock improves portfolio stability for funding global health and education programs.

Diversifying into holdings like Berkshire Hathaway matches standard practices for charitable endowments. The trust needs reliable liquidity for its mission.

Microsoft stock trades around $478 per share. Shares dropped 12% from their late-October high near $555.

The stock trades at nearly 13 times sales. Microsoft last hit this valuation during the dot-com bubble twenty years ago.

Strong Business Fundamentals Remain

Microsoft’s Azure cloud platform continues growing. The company plans $80 billion in data center spending this year.

Nvidia recently posted blowout earnings with 60% revenue growth. Those results confirm robust AI infrastructure spending, which benefits Azure directly.

The trust still owns over 9 million Microsoft shares. The $4.76 billion position represents a major holding, not a full exit.

No evidence suggests the sales reflect concerns about Microsoft’s business. The company generates strong free cash flow and trades at a lower forward P/E than many AI competitors after its pullback.

Azure growth accelerates while Copilot adoption expands across Microsoft’s product suite. The foundation’s selling appears driven by portfolio management needs rather than bearish views on the stock.

The post Microsoft (MSFT) Stock: Gates Foundation Offloads $9 Billion in Shares During Q3 appeared first on Blockonomi.

Market Opportunity
Intuition Logo
Intuition Price(TRUST)
$0.109
$0.109$0.109
-2.76%
USD
Intuition (TRUST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23